8-K: Esperion Therapeutics Reports Strong Q3 2024 Results Driven by Increased Product Revenue and Prescription Growth

Esperion Therapeutics announced a 52% year-over-year increase in total revenue to $51.6 million for the third quarter of 2024, fueled by growth in U.S. product sales and international partnerships.

Summary

• Esperion Therapeutics reported a 52% increase in total revenue to $51.6 million for the third quarter of 2024, compared to $34.0 million in the same period of 2023.
• U.S. net product revenue grew by 53% to $31.1 million in Q3 2024, driven by a 44% increase in retail prescriptions.
• Collaboration revenue increased by 50% to $20.5 million in Q3 2024, due to higher royalty sales and product sales to partners.
• Total retail prescription equivalents increased by 12% and new to brand prescriptions grew by 18% compared to the second quarter of 2024.
• October 2024 saw a further increase with total retail prescription equivalents up 17% and new to brand prescriptions up 20% compared to the first four weeks of Q3 2024.
• The company's net loss for Q3 2024 was $29.5 million, an improvement from the $41.3 million loss in Q3 2023.
• Research and development expenses decreased by 30% to $10.4 million in Q3 2024 due to the completion of the CLEAR Outcomes study.
• Selling, general, and administrative expenses increased by 20% to $40.0 million in Q3 2024, due to sales force expansion and promotional costs.
• Cash and cash equivalents totaled $144.7 million as of September 30, 2024, compared to $82.2 million at the end of 2023.
• The company reiterated its full-year 2024 operating expense guidance of $225 million to $245 million.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong revenue growth, increased prescriptions, and improved financial performance. The company is making significant progress in commercialization and international expansion. While there are still losses, the trend is positive, and the company is on track to achieve its goals.

Positives

• The company experienced significant revenue growth, with a 52% increase in total revenue year-over-year.
• U.S. product revenue saw a substantial 53% increase, indicating strong domestic sales performance.
• Prescription growth is robust, with a 12% increase in total retail prescription equivalents and an 18% increase in new to brand prescriptions compared to the previous quarter.
• The company has expanded access to its products through updated payer criteria and formulary additions, covering a large percentage of insured lives.
• International partnerships are progressing well, with strong European sales and a planned regulatory filing in Japan.
• The net loss has decreased compared to the same period last year, indicating improved financial performance.
• The company has a strong cash position with $144.7 million in cash and cash equivalents.

Negatives

• The company still reported a net loss of $29.5 million for the quarter, although it is an improvement from the previous year.
• Selling, general, and administrative expenses increased by 20%, primarily due to sales force expansion and promotional costs.
• The company is still reliant on collaboration revenue, which can be subject to external factors.

Risks

• The company is still operating at a loss, and continued losses could impact future financial stability.
• Increased selling, general, and administrative expenses could put pressure on profitability.
• The company is dependent on the success of its partnerships for international revenue.
• The company faces risks related to regulatory approvals and market acceptance of its products.
• The company's products have potential side effects, including hyperuricemia and tendon rupture, which could impact adoption.

Future Outlook

The company reiterates its full-year 2024 operating expense guidance of $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation. They anticipate continued growth in prescriptions and revenue, driven by expanded access and international partnerships.

Management Comments

• The year to date has been transformational for Esperion.
• We successfully expanded our product labels, scaled up our commercial team and launched new indications, which have driven double-digit prescription growth every quarter since receiving the new outcome labels.
• We are confident the advances we made in the third quarter with contracted payers and our innovative outreach to healthcare providers has strengthened our foundation for future growth.
• We continue to be impressed with and encouraged by the strong adoption and growing product revenue our European partner, Daichi Sankyo Europe (DSE), is generating across Europe.
• We also have a significant market opportunity in Japan where our partner, Otsuka Pharmaceutical, is advancing toward filing for regulatory approval of our bempedoic acid product by the end of 2024.

Industry Context

This announcement reflects a positive trend in the pharmaceutical industry, where companies focused on cardiovascular disease are seeing increased demand for innovative treatments. Esperion's growth is aligned with the broader industry push towards reducing LDL-C levels and preventing cardiovascular events. The company's success in securing payer coverage and expanding its commercial reach is also a key factor in its growth.

Comparison to Industry Standards

• Esperion's 52% year-over-year revenue growth in Q3 2024 is strong compared to many established pharmaceutical companies, which often see single-digit growth rates.
• The 53% growth in U.S. net product revenue indicates a successful commercial launch and market penetration, which is a key metric for pharmaceutical companies.
• The 12% increase in total retail prescription equivalents and 18% growth in new to brand prescriptions from the previous quarter are positive indicators of product adoption, which is a key metric for pharmaceutical companies.
• The company's success in securing formulary access for over 65% of Medicare insured lives and 92% of commercially insured lives is a significant achievement, as payer coverage is crucial for product success.
• Compared to companies like Amgen and Regeneron, which also focus on cardiovascular treatments, Esperion is demonstrating strong growth in a competitive market.
• The company's international partnerships with Daichi Sankyo and Otsuka are similar to strategies employed by other pharmaceutical companies to expand their global reach.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved financial performance positively.
• Employees may be encouraged by the company's progress and growth prospects.
• Patients will benefit from increased access to the company's products.
• Healthcare providers will have more confidence in prescribing the company's products due to expanded access and reduced restrictions.
• Partners will see the company's progress as a positive sign for future collaboration.

Next Steps

• Continue to drive prescription growth in the U.S. market.
• Advance regulatory filings in Japan, Canada, Australia and Israel.
• Present data at the American Heart Association Scientific Sessions.
• Continue to expand payer coverage and reduce access barriers.
• Monitor and manage operating expenses to achieve profitability.

Key Dates

Keywords

Esperion, bempedoic acid, NEXLETOL, NEXLIZET, cholesterol, LDL-C, cardiovascular, prescription, revenue, pharmaceutical, hyperlipidemia